ContextVision ABOSL:CONTX +6.97%81 EBITDA Margin % is 10.89% as of Mar. 2026, which is 64% below its 10-year median of 30.01. GuruFocus rates OSL:CONTX with a GF Score™ of 81/100 and a GF Value™ of kr5.13 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 665 Healthcare Providers & Services companies, ContextVision AB ranks better than 53.98% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ContextVision AB's EBITDA for the
three
months ended in Mar. 2026 was kr3.2 Mil. ContextVision AB's Revenue for the
three
months ended in Mar. 2026 was kr29.6 Mil. Therefore, ContextVision AB's EBITDA margin for the quarter that ended in Mar. 2026 was 10.89%.
ContextVision AB (OSL:CONTX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ContextVision AB EBITDA Margin % Related Terms
ContextVision AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ContextVision AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:CONTX vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, ContextVision AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ContextVision AB EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ContextVision AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ContextVision AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ContextVision AB (OSL:CONTX) has a EBITDA Margin % of 10.89% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ContextVision AB and its competitors. This is 64% below median its historical median of 30.01. Over the past decade, ContextVision AB's EBITDA Margin % has ranged from 3.61 to 60.96. According to the industry distribution chart, ContextVision AB ranks #306 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 46%.
Is ContextVision AB's EBITDA Margin % too high?
ContextVision AB's current EBITDA Margin % of 10.89% is 64% below median its 10-year median of 30.01. Over the past 10 years, this metric has ranged from a low of 3.61 to a high of 60.96. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. ContextVision AB's value of 10.89% is 6.3% above this industry median. Based on the distribution chart, ContextVision AB ranks #306 out of 665 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, ContextVision AB has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ContextVision AB's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ContextVision AB ranks #306 out of 665 companies for EBITDA Margin %. This puts ContextVision AB in the upper half of its industry. The industry median EBITDA Margin % is 10.24. ContextVision AB's value of 10.89% is 6.3% above this benchmark. Historically, ContextVision AB's own EBITDA Margin % has ranged from 3.61 to 60.96 over the past decade. While the company's 10-year median is 30.01 vs. the industry median of 10.24, ContextVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ContextVision AB's current EBITDA Margin % of 10.89% is 6.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ContextVision AB and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ContextVision AB's current EBITDA Margin % is 10.89%, which is 64% below median its own 10-year median of 30.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ContextVision AB stock overvalued right now?
Based on GuruFocus' analysis, ContextVision AB (OSL:CONTX) is currently considered Significantly Undervalued. The stock's GF Value™ is kr5.13, compared to a current price of kr3.53 — trading 31.2% below its estimated fair value. The current EBITDA Margin % is 10.89%, which is 64% below median its 10-year median of 30.01 and 6.3% above the Healthcare Providers & Services industry median of 10.24. ContextVision AB's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ContextVision AB (OSL:CONTX), the current EBITDA Margin % is 10.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ContextVision AB (OSL:CONTX) Overvalued in 2026?
Based on GuruFocus' analysis, ContextVision AB stock appears to be undervalued.
The current stock price of kr3.53 is trading 31.2% below its estimated GF Value™ of kr5.13.
GuruFocus considers ContextVision AB to be Significantly Undervalued.
Key valuation signals for OSL:CONTX:
EBITDA Margin %: 10.89% (64% below median its 10-year median of 30.01)
GF Value™: kr5.13 vs. price of kr3.53 (31.2% below fair value)
Industry Position: 6.3% above the Healthcare Providers & Services median (#306 of 665)
No single metric tells the full story. See the OSL:CONTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ContextVision AB is a medical technology company. It develops and sells image enhancement software for medical diagnosis and artificial intelligence. Its product portfolio includes image enhancement software for 2D/3D/4D (dimensional) ultrasound, magnetic resonance imaging (MRI), X-Ray, radiography, and mammography. Its geographical segments are Asia, Europe, and America.
81GF Score
Get the complete analysis for OSL:CONTX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:CONTX has been successfully added to your 
